Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).


TSXV:VPT - Post by User

Post by jopatcloon Apr 11, 2024 9:00am
144 Views
Post# 35982931

good new ."Dear Friend;

good new ."Dear Friend;
"Dear Friend;
 
Attached is today’s news release announcing a debenture financing.  The investors we have spoken to of late like the idea getting a 10% return on their investment while waiting.  We have added a feature to provide a “bonus of warrants” for  the holders should we have an early conversion event, which we believe will happen.
 
As usual, I (and other insiders) will be investing like I have done for every round of financing.  
 
We are so close to breakout and need to have a little more capital to continue to drive sales and allow version VMS+4.0 to get regulatory approvals.
 
Please let me know if you would like an allocation as I will be keeping track of this round and expect it to come together quickly.
 
Regards,
 
Dr. George Adams ICD.D
Executive-Chairman
Ventripoint Diagnostics Ltd.
TSXV-VPT
www.ventripoint.com
519-803-6937"
<< Previous
Bullboard Posts
Next >>